Lorlatinib is a third-gen ALK and ROS1 inhibitor. It goes after the kinases that are linked to the anaplastic lymphoma kinase (ALK) and the c-Ros oncoprotein tyrosine-protein kinase (ROS1). These are big players in NSCLC, especially when there’s an ALK-positive mutation.
Lorlatinib stops tumor cells from growing and has been effective in people with NSCLC that has spread after they’ve already tried other ALK inhibitors. You can get it as film-coated tabs in two doses, 25 mg and 100 mg. They usually suggest 100 mg a day for grown-ups, and you can take it with or without food.
Each bottle holds 30 Lorlatinib tabs, which is good for people who need to keep up their treatment for ALK-positive lung cancer after other ALK inhibitors didn’t work.
Reviews
There are no reviews yet.